Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May 21;10(11):2231.
doi: 10.3390/jcm10112231.

Autologous Micro-Fragmented Adipose Tissue (MFAT) to Treat Symptomatic Knee Osteoarthritis: Early Outcomes of a Consecutive Case Series

Affiliations

Autologous Micro-Fragmented Adipose Tissue (MFAT) to Treat Symptomatic Knee Osteoarthritis: Early Outcomes of a Consecutive Case Series

Wouter Van Genechten et al. J Clin Med. .

Abstract

The study aimed to evaluate the short-term clinical effect, therapeutic response rate (TRR%), and therapy safety of a single intra-articular autologous MFAT injection for symptomatic knee OA. Secondly, patient- and pathology-related parameters were investigated to tighten patient selection for MFAT therapy. Sixty-four subjects with symptomatic mild-severe knee OA were enrolled in a single-center trial and received a unilateral (n = 37) or bilateral (n = 27) MFAT injection. After liposuction, the adipose tissue was mechanically processed with the Lipogem® device, which eventually produced 8-10 cc of MFAT. Subjects were clinically assessed by means of the KOOS, NRS, UCLA, and EQ-5D at baseline and 1, 3, 6, and 12 months after injection. Adverse events were recorded at each follow-up timepoint. The TRR was defined according to the OMERACT-OARSI criteria and baseline MRI was scored following the MOAKS classification. The TRR of the index knee was 64% at 3 months and 45% at 12 months after injection. Therapy responders at 12 months improved with 28.3 ± 11.4 on KOOS pain, while non-responders lost -2.1 ± 11.2 points. All clinical scores, except the UCLA, improved significantly at follow-up compared to baseline (p < 0.05). In the bilateral cohort, no difference in baseline scores or TRR was found between the index knee and contralateral knee (n.s.). An inflammatory reaction was reported in 79% of knees and resolved spontaneously within 16.6 ± 13.5 days after MFAT administration. Numerous bone marrow lesions (BML) were negatively correlated with the TRR at 12 months (p = 0.003). The study demonstrated an early clinical improvement but a mediocre response rate of 45% at 12 months after a single intra-articular injection with autologous MFAT. Assessment of bone marrow lesions on MRI can be helpful to increase the therapeutic responsiveness of MFAT up to 70% at 12 months. In comparison to repetitive injection therapies such as cortisone, hyaluronic acid, and PRP, administration of MFAT might become a relevant alternative in well-selected patients with symptomatic knee OA.

Keywords: adipose tissue; autologous; biological; knee; osteoarthritis.

PubMed Disclaimer

Conflict of interest statement

One of the authors is a paid consultant for Lipogems® (Lipogems International SpA, Milan, Italy).

Figures

Figure 1
Figure 1
The OMERACT-OARSI criteria to define responding and non-responding subjects to treatment interventions in knee osteoarthritis. The therapeutic response rate (TRR%) is derived from this classification at respective follow-up timepoints after MFAT administration.
Figure 2
Figure 2
Flowchart of patient enrollment according to the standards of reporting trials statement with numbers of excluded and analyzed subjects. (MFAT, micro-fragmented adipose tissue; FU, follow-up).
Figure 3
Figure 3
KOOS outcomes of the index knees (n = 64) after a single injection with autologous MFAT. (ADL, activities of daily living; QoL, quality of living). * significant difference compared to baseline. ** significant difference compared to baseline and 1 month.
Figure 4
Figure 4
Overall therapeutic response rate (TRR) and associated absolute change in (a) KOOS pain and (b) KOOS activities of daily living (ADL) relative to baseline.
Figure 5
Figure 5
MOAKS outcome on baseline index knee MRI (n = 47). (MCCW, medial compartment cartilage wear; LCCW, lateral compartment cartilage wear; PFCW, patella-femoral cartilage wear; BML, bone marrow lesions).
Figure 6
Figure 6
Therapeutic response rate (TRR%) for bone marrow lesion (BML) classification.

References

    1. Zhang Y., Jordan J.M. Epidemiology of Osteoarthritis. Clin. Geriatr. Med. 2011;26:355–369. doi: 10.1016/j.cger.2010.03.001. - DOI - PMC - PubMed
    1. Levy D.M., Petersen K.A., Vaught M.S., Christian D.R., Cole B.J. Injections for Knee Osteoarthritis: Corticosteroids, Viscosupplementation, Platelet-Rich Plasma, and Autologous Stem Cells. Arthrosc. J. Arthrosc. Relat. Surg. 2018;34:1730–1743. doi: 10.1016/j.arthro.2018.02.022. - DOI - PubMed
    1. Deshpande B.R., Katz J.N., Solomon D.H., Yelin E.H., Hunter D.J., Messier S.P., Suter L.G., Losina E. The number of persons with symptomatic knee osteoarthritis in the United States: Impact of race/ethnicity, age, sex, and obesity. Arthritis Care Res. 2016;68:1743–1750. doi: 10.1002/acr.22897. - DOI - PMC - PubMed
    1. Ogden C.L., Carroll M.D., Kit B.K., Flegal M. Prevalence of Childhood and Adult Obesity in the United States. JAMA. 2016;311:806–814. doi: 10.1001/jama.2014.732. - DOI - PMC - PubMed
    1. Evans J.T., Walker R.W., Evans J.P., Blom A.W., Sayers A., Whitehouse M.R. How long does a knee replacement last? A systematic review and meta-analysis of case series and national registry reports with more than 15 years of follow-up. Lancet. 2019;393:655–663. doi: 10.1016/S0140-6736(18)32531-5. - DOI - PMC - PubMed